Covalent Inhibitor Warhead and Structure Property Inspector
Inspect the chemical structure and physicochemical descriptors of targeted covalent inhibitors bearing α,β-unsaturated acrylamide warheads, starting from the approved EGFR T790M inhibitor osimertinib. This reference explains how reversible scaffold recognition pairs with electrophilic bond formation and why covalent potency depends on incubation time.
Uses the shipped ChEMBL 37 osimertinib parent SMILES (CHEMBL3353410), pairing an aminopyrimidine reversible hinge-binding core with a terminal N-aryl acrylamide Michael acceptor warhead.
Separate non-covalent scaffold recognition from warhead reactivity
Modern targeted covalent inhibitors combine two distinct structural elements in one molecular graph: a selective non-covalent recognition scaffold that binds a defined pocket (governed by KI) and a weakly reactive warhead positioned to react with a non-catalytic nucleophilic residue such as cysteine, lysine or tyrosine (governed by kinact). In osimertinib, the substituted pyrimidine core engages the EGFR kinase hinge region while the meta-acrylamide group reaches Cys797 at the lip of the ATP pocket.
Inspecting osimertinib alongside ibrutinib (CHEMBL1873475) or afatinib (CHEMBL1173655) in the molecule workbench shows that successful oral covalent drugs generally maintain Lipinski and Veber physicochemical profiles similar to reversible inhibitors, because they still must dissolve, cross cell membranes and survive systemic circulation prior to target engagement.
Pair covalent structure inspection with time-dependent kinetic assays
When evaluating a covalent series, measure time-dependent IC50 shifts or continuous progress curves to extract kinact, KI and the second-order specificity constant kinact/KI, and check intrinsic thiol reactivity against reduced glutathione (GSH t1/2) under physiological pH and temperature.
Equations and variables
Two-step irreversible covalent inactivation scheme
E + I ⇌ E·I (KI) → E–I (kinact); kobs = (kinact × [I]) / (KI + [I])
- KI
- Concentration of inhibitor giving half-maximal inactivation rate (reversible binding affinity) (mol/L)
- kinact
- Maximum first-order rate constant of covalent bond formation within the E·I complex (s⁻¹)
- kobs
- Observed pseudo-first-order rate constant of enzyme inactivation at inhibitor concentration [I] (s⁻¹)
- kinact / KI
- Second-order covalent efficiency constant governing target engagement rate and selectivity (M⁻¹ s⁻¹)
Average molecular weight
MW = Σ ni Mi
- ni
- Count of atoms of element i in the represented structure
- Mi
- Average atomic mass used by the engine (g/mol)
- MW
- Molar mass of the represented structure (g/mol)
Scope and limitations
- Whole-molecule 2D descriptors (MW, cLogP, TPSA) describe the unreacted parent structure before covalent thiol addition and do not predict intrinsic glutathione reactivity or kinact/KI.
- An endpoint IC50 measured for an irreversible covalent inhibitor decreases over incubation time as more enzyme becomes inactivated; quoting a single IC50 without the pre-incubation duration is incomplete.
- The structure workbench does not simulate quantum-mechanical electrophilicity or covalent docking to a specific protein cysteine.
Sources and provenance
- RDKit descriptor implementation and versioned reference checksBSD-3-Clause
Method implementation; computed molecular properties are estimates.
- ChEMBL 37 parent structures in the shipped compound libraryCC BY-SA 3.0; share-alike
Existing library capture: 28 September 2026. Preserve attribution when redistributing its rows.
- Wildman and Crippen: atomic contributions to molecular propertiesCited method; no reproduced article data
- Ertl, Rohde and Selzer: fast calculation of molecular polar surface areaCited method; no reproduced article data
- Strelow: a perspective on the kinetics of covalent and irreversible inhibitionCited method; kinact/KI kinetic characterisation
- Cross et al.: AZD9291 (osimertinib), an irreversible EGFR TKI targeting T790M resistanceArticle citation; osimertinib discovery context
Technical questions
Why do targeted covalent inhibitors use tuned acrylamides instead of highly reactive electrophiles?
Highly reactive electrophiles modify off-target proteins and intracellular glutathione indiscriminately, causing idiosyncratic toxicity and rapid clearance. A weakly electrophilic acrylamide reacts slowly in bulk solution but forms a covalent bond rapidly once held in close proximity to a nucleophilic cysteine (such as Cys797 in EGFR or Cys481 in BTK) by high-affinity reversible binding (low KI).
Why does the measured IC50 of a covalent inhibitor shift with pre-incubation time?
In a two-step irreversible reaction, the fraction of uninhibited enzyme decays exponentially over time at rate kobs. Extending the enzyme–inhibitor pre-incubation from fifteen minutes to two hours allows lower inhibitor concentrations to complete the covalent reaction, shifting the apparent IC50 downward until it hits the active-site titration limit.
How does the workbench handle the unreacted acrylamide double bond?
The descriptor engine analyses the drawn parent structure as a standard organic molecule, counting the acrylamide carbonyl and NH in TPSA and HBD/HBA. It has no Michael-acceptor or reactivity alert, and osimertinib matches no PAINS pattern, so the warhead must be recognised by the chemist.
Connected workflows
- EGFR sequence and structure inspection
Read why the EGFR ectodomain structure (4UV7) lacks residues 790 and 797, and which entry holds the kinase domain.
- 4PL IC50 curve fitting
Review why endpoint IC50 curves require explicit incubation-time reporting.
- KRAS G12D trial-record exploration
Explore covalent and non-covalent targeted oncology clinical trial landscapes.